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associated with remission status at follow-up. Substance use in the
year after psychosis onset was associated with increased probability of
poor medication adherence during the follow-up. In particular, the
analysis showed signiﬁcant main effects of nicotine dependence
(OR= 2.18), cannabis use (OR= 2.86), and stimulant use (OR= 2.63) on
the odds of being non adherent to treatment. In contrast, the OR
failed to reach signiﬁcance for an association between problem
drinking and poor medication adherence.
Substance use in the ﬁrst year after psychosis onset was associated
with increased probability of non-remission during the one year
follow-up. In particular, the analysis showed signiﬁcant main effects of
nicotine dependence (OR= 2.13) and cannabis use (OR= 2.60) on
probability of not achieving remission. In contrast, the ORs failed to
reach signiﬁcance for an association between problem drinking and
non-remission as well as between stimulant use and non-remission.
Medication adherence signiﬁcantly predicted remission during the
one year follow-up. In particular, patients with poor medication
adherence showed a six-fold increased probability of non-remission of
their psychosis when compared with patients with good medication
adherence. When substance use in the one year follow-up period was
added in to this model, the association between medication
adherence and remission was still signiﬁcant. Following Baron and
Kenny’s approach to mediation, criteria were satisﬁed only for nicotine
dependence and cannabis use post onset. In order to test for
mediation, the associations between nicotine dependence after
psychosis onset and non-remission as well as between cannabis use
and non-remission were adjusted for medication adherence. When
medication adherence was added in to the model, even if increased,
the ORs failed to reach signiﬁcance. Sobel tests for mediation showed
that medication adherence was a signiﬁcant mediator of the
relationship between nicotine dependence and remission (z=2.02,
P= 0.04) as well as that between cannabis use and remission (z=2.12,
P= 0.03).
Discussion: In conclusion, medication adherence lies on the causal
pathway between nicotine dependence and cannabis on the one
hand and non-remission on the other. As cannabis and tobacco are
often consumed together in the same joint and there is accumulating
evidence of a common underlying vulnerability to both substances,
further research is needed to deﬁnitively disentangle their indepen-
dent contribution on patients’ clinical outcome.
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Background: People with schizophrenia have a life expectancy 15 years
less than the general community, and much higher rates of chronic
diseases such as cardiovascular disease, diabetes and obesity. In
response to this disproportionately high burden of illness the ﬁrst
Australian National Report Card on Mental Health stated “the reduced
life expectancies and poor health of people with the most severe
mental illnesses…is a national disgrace and it should be a major
public health concern”. Telephone interventions for health behaviors
(such as smoking, alcohol use, low fruit and vegetable consumption
and high levels of sedentary activity) as well as for psychotic
symptomatology and also smartphone applications have been
evaluated with promising results. This is the ﬁrst randomized
controlled trial to evaluate a cognitive-behavioral intervention
addressing smoking and other health behaviors among people with
psychotic disorders.
Methods: Study participants were randomly assigned to receive a
single face to face session consisting of feedback and motivational
interviewing and nicotine replacement therapy, plus either: (i) a face-
to-face intervention targeting multiple health risk behaviors; or (ii) a
predominantly telephone delivered intervention involving monitor-
ing. Follow-up surveys were completed at 15 weeks (n= 165, 70.2%),
12 months (n= 139, 59%), 18 months (n=132, 56.2%), 24 months
(n=133, 56.6%), 30 months (n= 129, 54.9%) and 36 months (n= 134,
57%). ITT analysis was used for primary outcomes and mixed models
were used for both primary and secondary modeling, so all study
participants were included in analyses.
Results: At baseline, participants (N= 235, Age, M= 41.6 years, 59%
male) were smoking on average 28.6 (SD= 15.3) CPD. There were no
signiﬁcant overall differences between the telephone and face-to-face
conditions in the primary smoking outcome of biochemically
conﬁrmed point-prevalence abstinence rates (8% and 11% respec-
tively) at 36 months. There were no signiﬁcant differences between
groups in most measures of exercise, diet and body measures (total
minutes walking per week, total minutes sitting per week, BMI, waist
circumference, weight, waist-to-hip ratio).
Discussion: Face-to-face and telephone-delivered interventions are
feasible and effective among people with severe mental disorders for
smoking. Interventions for multiple health behavior change appear
worthy of further research among people with psychotic disorders.
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Background: Cannabis is frequently used by people with ﬁrst episode
psychosis (FEP), though its effect on clinical outcome is less clear. We
investigated whether cannabis use may be associated with increased
risk of hospitalization and whether antipsychotic treatment failure, as
indexed by number of unique antipsychotics prescribed, may mediate
this effect in a large dataset of patients with FEP.
Methods: Data were obtained from electronic health records of 2,026
people with FEP in the South London and Maudsley NHS Foundation
Trust (SLaM) using the Clinical Record Interactive Search tool (CRIS).
Cannabis use was identiﬁed using natural language processing. Data on
subsequent hospital admission and the number of unique antipsycho-
tics prescribed (a marker of treatment failure) were obtained and
analyzed using multivariable regression and mediation analyses with
age, gender, ethnicity, marital status and diagnosis as covariates.
Results: Cannabis use was present in 46.3% of the sample at ﬁrst
presentation and was particularly common in patients who were
16-25, male and single. It was associated with increased frequency of
hospital admission (incidence rate ratio 1.50, 95% CI 1.25 to 1.80),
increased likelihood of compulsory admission (odds ratio 1.55, 1.16 to
2.08) and greater number of inpatient days (B coefﬁcient 35.1 days,
12.1 to 58.1). Antipsychotic treatment failure mediated increased
frequency of hospital admission (natural indirect effect: 1.09, 95% CI
1.01 to 1.18; total effect: 1.50, 1.21 to 1.87), increased likelihood of
compulsory admission (NIE: 1.27, 1.03 to 1.58; TE: 1.76, 0.81 to 3.84)
and greater number of inpatient days (NIE: 17.9, 2.4 to 33.4; TE: 34.8,
11.6 to 58.1).
Discussion: Cannabis use in patients with FEP was associated with
increased likelihood and duration of hospital admission. This was
linked to the prescription of several different antipsychotic drugs,
indicating clinical judgement of antipsychotic treatment failure. This
suggests that cannabis use might be associated with worse clinical
outcomes in psychosis by contributing towards failure of antipsycho-
tic treatment.
M112. Better social but worse academic premorbid adjustment
in cannabis-users psychotic patients across Europe
Laura Ferraro1, Capuccio Veronica1, Caterina La Cascia1, Lucia Sideli1,
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Background: Several studies report that patients with psychosis who
used cannabis have a better cognitive performance than those who
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